Skip to content
TrialScanner

NCT05153330

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

Phase 1TerminatedBMEALead

Registry record

Lead sponsor
Biomea Fusion Inc.
Conditions
Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Mixed-Phenotype Leukemia; Cancer; Refractory
Primary completion
Feb 13, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05153330 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05153330: Study of BMF-219, a Covalent... | TrialScanner